Drug intelligence / Profile preview

ABVD + ABVE-PC

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

ABVD and ABVE-PC are two distinct chemotherapy regimens used for treating Hodgkin lymphoma. They are not typically administered together but represent different treatment approaches for different patient populations. ABVD consists of: - Doxorubicin (Adriamycin) - Bleomycin - Vinblastine - Dacarbazine ABVE-PC consists of: - Doxorubicin (Adriamycin) - Bleomycin - Vincristine - Etoposide - Prednisone - Cyclophosphamide ABVD is primarily used in adults with Hodgkin lymphoma, while ABVE-PC is more commonly used in pediatric patients with intermediate or high-risk Hodgkin lymphoma. Both regimens work by destroying rapidly dividing cancer cells through different mechanisms.

Targets

TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on ABVD + ABVE-PC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABVD + ABVE-PC.

Explore the full profile